Abstract
Introduction: Ischemic stroke (IS) is a major cause of death and disability worldwide. The P2Y12 receptor plays a critical role in the formation of a stable thrombus leading to ischemic complications. Therefore, P2Y12 receptor inhibitors constitute a major antiplatelet strategy in the secondary prevention of IS.Areas covered: We searched articles about P2Y12 receptor inhibitors and stroke in PubMed published until December 2014. This is a comprehensive review of the role of P2Y12 receptor inhibitors alone and in combination with aspirin in the secondary prevention of noncardioembolic stroke.Expert opinion: The potential benefit of more potent antiplatelet therapy for secondary stroke prevention must be weighed against the risk of bleeding in patients with IS. Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient.
Original language | English (US) |
---|---|
Pages (from-to) | 1149-1165 |
Number of pages | 17 |
Journal | Expert opinion on pharmacotherapy |
Volume | 16 |
Issue number | 8 |
DOIs | |
State | Published - Jun 1 2015 |
Keywords
- Clopidogrel
- P2Y receptor inhibitor
- Prasugrel
- Stroke
- Ticagrelor
- Ticlopidine
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)